Thus far, identification of putative resistance mechanisms to KRAS inhibition has largely relied on sequencing circulating tumor DNA (ctDNA) from relapsed lung and colon cancer patients, using targeted gene panels (112–116). This evidence concerns the gene KRAS and malignant colon neoplasm.